What's new?

Added 22 hours ago Drug news

Phase III INVICTUS study results positive for ripretinib in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors.-Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals, Inc. announced positive top-line data from the INVICTUS pivotal Phase III clinical study of ripretinib, a broad-spectrum KIT...

Added 1 day ago Drug news

FDA approves Inrebic to treat primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.- Celgene

Celgene Corporation announced the FDA has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary...

Added 1 day ago Drug news

EMA accepts MAA for filgotinib to treat rheumatoid arthritis .- Gilead Sciences + Galapagos NV

Gilead Sciences, Inc. and Galapagos NV announced that the Marketing Authorization Application (MAA) for filgotinib , an investigational, oral, selective...

Added 1 day ago Drug news

FDA approves Rozlytrek to treat ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors- Genentech/Roche

Genentech has announced that the FDA has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell...

Added 1 day ago Drug news

FDA approves Rinvoq to treat moderately to severely active rheumatoid arthritis . AbbVie.

AbbVie has announced that the FDA has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for...